Biotech companies prepare for COVID-19 downturn

Share

Private biopharma investment and fundraising has seemed unaffected by the global pandemic. US venture funding for the sector reached $5.5B in the first three months of 2020, reflecting biopharma’s strong long-term fundamentals as well as its role against the virus. However, it’s still early…

If COVID-19-linked disruption lasts longer than six months, even well-capitalized sectors must prepare for the consequences. The effects of lockdown across most major economies have yet to be fully felt, and it’s unclear what damages lie ahead when restrictions are lifted.

Read the full article at nature.com…

Share

Comments are closed.